Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-08-16
2011-08-16
Kifle, Bruck (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C540S497000, C540S498000
Reexamination Certificate
active
07998954
ABSTRACT:
The invention provides a pyrimidodiazepinone derivative represented by the general formula (I)[wherein n represents 1 or 2, Z represents a hydrogen atom or the like, R1and R2may be the same or different, and each represents a hydrogen atom or the like, A represents a bond, (CH2)m(wherein m represents an integer of 1 to 4), optionally substituted phenylene, optionally substituted pyridinediyl, or C═O, R3represents a hydrogen atom, optionally substituted lower alkyl, or the like, and R4represents a hydrogen atom or the like], or a pharmaceutically acceptable salt thereof or the like.
REFERENCES:
patent: 6656935 (2003-12-01), Yamada et al.
patent: 6797709 (2004-09-01), Yamada et al.
patent: 7064119 (2006-06-01), Seto et al.
patent: 7220736 (2007-05-01), Yamada et al.
patent: 7273868 (2007-09-01), Yamada et al.
patent: 2004/0142930 (2004-07-01), Yamada et al.
patent: 2005/0159409 (2005-07-01), Seto et al.
patent: 2005/0256102 (2005-11-01), Claiborne et al.
patent: 2006/0154929 (2006-07-01), Anker et al.
patent: 2007/0185087 (2007-08-01), Claiborne et al.
patent: 2008/0027037 (2008-01-01), Yamada et al.
patent: 2005-536507 (2005-12-01), None
patent: WO-01/83460 (2001-11-01), None
patent: WO-03/080619 (2003-10-01), None
patent: WO-2004/006836 (2004-01-01), None
patent: WO-2005/111039 (2005-11-01), None
Catterall, “Structure and Regulation of Voltage-Gated Ca2+Channels”, Annual Review of Cell and Developmental Biology, 2000, vol. 16, pp. 521-555.
Davies et al., “Functional biology of the α2δ subunits of voltage-gated calcium channels”, Trends in Pharmacological Sciences, 2007, vol. 28, No. 5, pp. 220-228.
Dooley et al., “Ca2+channel α2δ ligands: novel modulators of neurotransmission”, Trends in Pharmacological Sciences, 2007, vol. 28, No. 2, pp. 75-82.
Gee et al., “The Novel Anticonvulsant Drug, Gabapentin (Neurontin), Binds to the α2δ Subunit of a Calcium Channel”, The Journal of Biological Chemistry, 1996, vol. 271, pp. 5768-5776.
Gong et al., “Tissue-specific Expression and Gabapentin-Binding Properties of Calcium Channel α2δ Subunit Subtypes”, Journal of Membrane Biology, 2001, vol. 184, pp. 35-43.
Fukuyama et al., “N-Carboalkoxy-2Nitrobenzenesulfonamides: A Practical Preparation ofN-Boc-,N-Alloc-, andN-Cbz-Protected Primary Amines”, Synlett, 1999, No. 8, 1301-1303.
Seto et al., “Design, synthesis, and evaluation of novel 2-substituted-4-aryl-6,7,8,9-tetrahydro-5H-pyrimido-[4,5-b][1 ,5]oxazocin-5-ones as NK1antagonists”, Bioorganic & Medicinal Chemistry, 2005, vol. 13, pp. 5717-5732.
Suman-Chauhan et al., “Characterisation of [3H]gabapentin binding to a novel site in rat brain: homogenate binding studies”, European Journal of Pharmacology—Molecular Pharmacology Section, 1993; 244: 293-301.
Mosconi et al., “Fixed-diameter polyethylene cuffs applied to the rat sciatic nerve induce a painful neuropathy: ultrastructural morphometric analysis of axonal alterations”, Pain, 1996, vol. 64, pp. 37-57.
Dixon, “Efficient Analysis of Experimental Observations”, Annual Review of Pharmacology and Toxicology, 1980, vol. 20, pp. 441-462.
Kitagaki et al., “Immediate-Type Hypersensitivity Response Followed by a Late Reaction Is Induced by Repeated Epicutaneous Application of Contact Sensitizing Agents in Mice”, Journal of Investigative Dermatology, 1995, vol. 105, pp. 749-755.
Kuraishi et al., “Scratching behavior induced by pruritogenic but not algesiogenic agents in mice”, European Journal of Pharmacology, 1995, vol. 275, pp. 229-233.
Tempest et al., “MCC/SnAr methodology. Part 1: Novel access to a range of heterocyclic cores”, Tetrahedron Letters, 2001, vol. 42, No. 30, pp. 4963-4968.
Arai Hitoshi
Iida Kyoichiro
Imaizumi Takamichi
Okazaki Shuko
Otsubo Nobumasa
Conlin David G.
Edwards Angell Palmer & & Dodge LLP
Kifle Bruck
Kyowa Hakko Kirin Co., Ltd.
Russett Mark D.
LandOfFree
Pyrimidodiazepinone derivative does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrimidodiazepinone derivative, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrimidodiazepinone derivative will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2742260